Ozmosi | Pyrazinamide Drug Profile

Product Description

Pyrazinamide (PZA) is a unique antituberculosis (anti-TB) drug that plays a key role in shortening TB therapy. PZA kills nonreplicating persisters that other TB drugs fail to kill, which makes it an essential drug for inclusion in any drug combinations for treating drug-susceptible and drug-resistant TB such as multidrug-resistant TB. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26104205/)

Mechanisms of Action: Fatty Acid Synthesis Inhibitor, Fatty Acid Synthetase Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Indications: None

Known Adverse Events: None

Company: Hongqi Pharmaceutical
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pyrazinamide

Countries in Clinic: China, Gabon, Malawi, Mozambique, South Africa, Tanzania, Uganda

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Tuberculosis, Pulmonary

Phase 1: Tuberculosis

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
CTR20241168	P1	Completed	Tuberculosis	2024-04-30		2025-06-22	Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
PanACEA - STEP2C -01	P2	Recruiting	Tuberculosis, Pulmonary	2027-10-31	50%	2025-10-08	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date

Recent News Events

Date	Type	Title
10/06/2025	News Article	Customer Loyalty Program Software Market Projected to Reach USD 10.3 Billion by 2033, Amid Rising Digital Engagement, and Advanced Analytics Integration - Market Research Intellect
10/06/2025	News Article	Dry Ice Making Equipment Market to Reach USD 800 Million by 2033 at a Robust CAGR of 6.5% from 2026-2033 - Market Research Intellect
08/27/2025	News Article	BioVersys Receives EMA Orphan Designation for the Combination of Alpibectir and Ethionamide for the Treatment of Tuberculosis
11/29/2024	News Article	Antibiotics and Antimycotics Market Size to Hit $91.54 Billion, Globally at 5.2% CAGR by 2031 - Exclusive Report by The Insight Partners

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Pyrazinamide

Alternative Names: pyrazinamide, rifafour, pyrazinamid, rifater Clinical Status: Inactive Latest Update: 2025-10-07 Latest Update Note: Clinical Trial Update